Sensyne Health inks five year SRA with Hampshire Hospitals NHS Foundation Trust
has signed a five year non-exclusive Strategic Research Agreement (SRA) with Hampshire Hospitals NHS Foundation Trust which will enable the ethical application of clinical artificial intelligence research on anonymised patient data.
The UK Clinical AI company said the agreement will enable this ethical application of clinical AI research in order to improve patient care and accelerate research into new medicines.
As part of the SRA, Hampshire Hospitals will receive 1,428,571 ordinary Sensyne shares, bringing the total share ownership held by NHS Trusts in Sensyne Health to 12.6%. It will also receive £0.25m per year from Sensyne over the 5-year term contract for specific investments in information technology to enable the curation and analysis of data under the SRA.
Sensyne said Hampshire Hospitals will receive a royalty on revenues that are generated by Sensyne from the research undertaken under the SRA. The financial return Hampshire Hospitals receives from Sensyne will be reinvested back into the NHS to fund patient care.
The Hampshire Hospitals dataset covers 500,000 unique patient records, with 200,000 annual hospital admissions from a patient population of around 570,000 people. Its dataset includes oncology data that will enable Sensyne to build on its existing research into rare cancers.
The agreement with Hampshire Hospitals, which provides hospital services to the populations of Hampshire and parts of West Berkshire and hosts around 6,000 staff, now brings the combined total of anonymised data available for analysis by Sensyne to 6.1 million patients.
Hampshire Hospitals offers a range of specialist services to regional and national populations including surgical treatment for Pseudomyxoma Peritonei, a rare, chronic abdominal cancer, liver and colorectal cancer surgery, as well as intraoperative radiotherapy for breast cancer.
Shares in Sensyne Health have skyrocketed over 140% since the beginning of October 2020 to open 3.60% higher this morning at 144p following the announcement.
Sensyne noted that Hampshire Hospitals is also the network host for a regional haemophilia service that serves a wide population across Hampshire, Dorset, Sussex and Wiltshire.
The company said its research will be undertaken ‘to the highest standards’ in accordance with NHS principles, the UK Government Code of Practice and data protection legislation.
All data supplied to Sensyne will be anonymised by Hampshire Hospitals beforehand and the provision of the data will operate under an agreed Data Processing Protocol ("DPP") under Hampshire Hospitals ethical oversight.
Hampshire Hospitals joins existing SRAs the Company has in place with Oxford University Hospitals NHS Foundation Trust, Chelsea & Westminster Hospitals NHS Foundation Trust, South Warwickshire NHS Foundation Trust, Wye Valley, George Eliot NHS Trusts, Milton Keynes University Hospital NHS Foundation Trust and Somerset NHS Foundation Trust.
“We are very pleased to be working alongside Hampshire Hospitals NHS Foundation Trust which now brings our overall anonymised data set to over 6.1 million patients and thereby helps us to broaden our research,” said Lord (Paul) Drayson PhD, CEO of Sensyne Health.
He added, “Importantly, our agreement with Hampshire Hospitals and their oncology expertise now allows us to build on our capabilities in researching rarer forms of cancer."
“Following the recent achievement of our original patient data goal we'll continue to use our resources efficiently, to add data consistent with our strategy of providing an unparalleled research resource for the healthcare and pharmaceutical sectors."
For more news and updates on Sensyne Health:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.